OraSure Technologies, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone Q4 report; the supplied text gives only limited fourth-quarter detail. OraSure develops and sells diagnostic tests and specimen-collection products and services through its Diagnostics and Molecular Solutions segments.
Financial results and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Net revenue | $233.7 million | $171.7 million |
| Gross profit / gross margin | $117.6 million / 50% | $101.9 million / 59% |
| Operating loss | $10.2 million | $5.2 million |
| Net loss | $23.0 million; $0.32 per diluted share | $14.9 million; $0.22 per diluted share |
| Cash from operating activities | Used $35.4 million | Provided $5.8 million |
| Cash, cash equivalents and available-for-sale securities | $170.0 million | $257.1 million |
| Working capital | $220.4 million | $242.4 million |
Revenue rose 36%, while gross margin fell nine percentage points and the net loss widened. The filing attributes margin pressure chiefly to InteliSwab manufacturing scrap and inefficiencies, inventory adjustments, lower labor utilization, reduced Gates Foundation subsidies and product mix. Operating cash use reflected, in part, a $27.9 million inventory build for expected COVID-19 test demand. Capital expenditures were $36.6 million, excluding $11.5 million of property and equipment purchased under the DOD funding arrangement.
The balance sheet reported no borrowings in the presented liabilities; lease liabilities totaled approximately $12.3 million. Current assets were $288.4 million and current liabilities $68.1 million. Income tax expense was $13.7 million despite a pretax loss, largely reflecting foreign tax expense. OraSure maintained a full valuation allowance against its U.S. deferred tax assets.
Business and material changes
- Diagnostics segment revenue was $90.0 million, up 38%; segment operating loss was $57.2 million. Molecular Solutions revenue was $143.6 million, up 35%; segment operating income was $47.0 million.
- COVID-19-related revenue included $22.4 million of InteliSwab sales, which began shipping in August, and $54.2 million from molecular COVID-19 collection kits. Genomics revenue grew 72% to $63.4 million; OraQuick HIV revenue declined 5% to $42.1 million, mainly due to lower international sales.
- OraSure received three FDA Emergency Use Authorizations for InteliSwab in June 2021. The company reported manufacturing scale-up and technology-transfer challenges that constrained its ability to meet demand and contributed to scrap and inventory charges.
- In September 2021, the DLA awarded an InteliSwab procurement contract estimated by the agency at $205 million, covering October 2021 through September 2022. OraSure recognized $1.9 million of related revenue in Q4 2021. The filing describes coverage of up to 20,000 sites in one section and 25,000 in another.
- The DOD agreed to provide $109 million, subject to milestones through March 2024, to expand annual U.S. InteliSwab capacity by 100 million tests. The company reported receiving $15.4 million by the filing date, after year-end. BARDA funding of up to $13.6 million supports work toward FDA 510(k) clearance and a CLIA waiver.
- The board was exploring strategic alternatives, with no assurance of a transaction. In January 2022, the company announced its intention to evaluate a broad range of alternatives. The CEO’s departure was scheduled for March 31, 2022; the filing records a $1.6 million severance accrual at year-end.
Outlook, risks and unusual items
No numerical revenue, earnings or cash-flow guidance is provided. Management stated that existing cash and investments were expected to fund current and foreseeable operating and capital needs, while noting that requirements could change. It also reported a $65 million repatriation from its Canadian subsidiary in 2022, with Canadian withholding taxes expected. About 80% of year-end cash, cash equivalents and securities was held by the Canadian subsidiary.
Key risks include uncertain and potentially declining COVID-19 testing demand; InteliSwab manufacturing scale-up, quality and government-contract execution; dependence on government funding and customer purchasing patterns; supply-chain constraints and sole-source suppliers; competition and regulatory requirements; and volatility in genomics and research markets. COVID-19 collection-kit demand declined in the second half of 2021 as rapid tests became more available. The company recorded $13.4 million of inventory adjustments during 2021, including a $3.0 million write-off of COVID-19 antibody inventory after it stopped pursuing an EUA for that test. KPMG issued an unqualified opinion on the financial statements and internal control over financial reporting; inventory valuation was identified as a critical audit matter. OraSure reported a patent-infringement lawsuit against Spectrum Solutions, which also asserted counterclaims; the outcome was unresolved.
Important facts for investors to verify
- Whether InteliSwab production improved sufficiently to fulfill customer demand and the DLA contract, and how much of the estimated contract value was ultimately realized.
- The DLA site-count discrepancy: 20,000 sites in one filing section versus 25,000 in another.
- Milestone completion, reimbursement timing and final costs for the $109 million DOD manufacturing-capacity project, including the reported post-year-end receipts.
- The sustainability and margins of COVID-related sales, alongside recovery in HIV, HCV, genomics and microbiome markets.
- The effects of the strategic-alternatives review, CEO transition and $65 million cash repatriation, including related tax costs and the availability of funds in the United States.